Tetraphase Pharmaceuticals President & CEO Guy Macdonald to Present at 2011 BIO International Convention

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the company will present at the 2011 BIO International Convention being held June 27 to 30 in Washington, D.C. at the Walter E. Washington Convention Center. Tetraphase President and Chief Executive Officer Guy Macdonald will participate in a panel entitled “Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms,” which will take place on Tuesday, June 28, from 10:00 a.m. until 11:30 a.m.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and Gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit http://www.tphase.com.


Sam Brown Inc.
Mike Beyer, 773-463-4211
[email protected]

KEYWORDS:   United States  North America  District of Columbia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical



Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.